A pilot clinical study to Evaluate Liraglutide-mediated Anti-platelet activity in patients with type-2 Diabetes (ELAID study)

Jayasree Loganathan, Adam C. Cohen, Georgia M. Kaloupis, Carolyn Harris, Andriana Chronopoulos, Vanessa James, Justin Hamilton, Sarah Green, Andrew Wallis, Susan Morgan, Raymond Dauer, Christopher Gilfillan, Anthony E. Dear

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)


Background: Liraglutide is an effective treatment for the management of type 2 diabetes mellitus (T2DM). In addition to glycemic control and potential cardioprotective effects, recent studies suggest a possible role for liraglutide in the inhibition of platelet reactivity, further attenuating atherothrombotic risk in patients with T2DM. We evaluated the in-vivo antiplatelet effect of liraglutide in T2DM patients without macrovascular disease or concurrent anti-platelet therapy. Methods: A double-blind, placebo-controlled pilot study of 16 T2DM patients, 51–69 y/o, (mean age 60.4 y/o, 63.0% male) randomised to receive liraglutide (1.8 mg/day) or placebo (saline) for 6 months was conducted. Platelet aggregation studies at baseline and after initiation of the study intervention: days 1, 7, and 14 and months 1, 3 and 6 were performed. Results: Liraglutide (n = 7) and placebo (n = 9) treated patients demonstrated normal platelet aggregation responses although transient and significant attenuation in maximum slope of platelet aggregation in response to collagen (p ≤ 0.05), arachidonic acid (p ≤ 0.05) and ADP (p ≤ 0.02) was observed in liraglutide compared to placebo treated patients in the first week. Conclusions: In this pilot study of patients with T2DM liraglutide treatment was associated with a significant, early and transient decrease in maximum slope of platelet aggregation. The clinical significance of this effect is currently unknown and may warrant further investigation. Clinical Trial Registration Number: UTN 1111-1181-9567.

Original languageEnglish
Article number108188
Number of pages8
JournalJournal of Diabetes and its Complications
Issue number5
Publication statusPublished - May 2022


  • Antiplatelet
  • Glucagon-like peptide-1 receptor (GLP-1R)
  • Liraglutide
  • Thrombosis
  • Type 2 diabetes mellitus

Cite this